<DOC>
	<DOCNO>NCT00795977</DOCNO>
	<brief_summary>The purpose study confirm safety immunological response Preoperative intratumor dendritic cell injection immunotherapy use immature dendritic cell S pyogenes Preparation ( OK-432 ) patient resectable pancreatic cancer pancreatic cancer patient .</brief_summary>
	<brief_title>Preoperative Intratumor Dendritic Cells Injection Immunotherapy Patients With Pancreatic Cancer</brief_title>
	<detailed_description>The prognosis pancreatic cancer extremely poor even extensive surgery , development new treatment modality much-expected cure disease . Dendritic cell ( DCs ) immunotherapy expect favorable outcome approach directly cancer tissue . To evaluate safety immunological response , conduct phase I/II study intra-tumor DCs immunotherapy pancreatic cancer patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Picibanil</mesh_term>
	<criteria>Resectable pancreatic cancer without distant metastasis : 1 . ECOG performance status 02 2 . Laboratory value follow 3,500/mm3 &lt; WBC &lt; 12000/mm3 Platelet count &gt; 100,000/mm3 TBil &lt; 2.0mg/dl BUN &lt; 25mg/dl , Creatinin &lt; 1.5mg/dl , 24h Ccr &gt; 50ml/min Normal ECG 3 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeder 3 . Active uncontrolled infection 4 . Active uncontrolled malignancy 5 . Steroids immunosuppressing agent dependant status 6 . Interstitial pneumonia 7 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>preoperative</keyword>
	<keyword>intratumor</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>OK-432</keyword>
</DOC>